Advantage Solutions Ranks No. 18 Globally   Largest Agency Based in St. Louis ST. LOUIS, June 26, 2026 (GLOBE NEWSWIRE) — Advantage Solutions Inc. (NASDAQ: ADV), the leading omnichannel retail solutions agency in North America, has been named the 18th largest agency company worldwide in the Ad Age Agency Report 2026, which ranks the top 25 global agency companies by revenue. The ranking also makes Advantage Solutions the largest agency headquartered in St. Louis, driven by $1.22 billion in revenue from its marketing and experiential solutions business, including AMP (Advantage Marketing Partners), its full-service marketing agency. “Advantage Solutions operates across the entire path to purchase, and that full-picture view is what makes our marketing and experiential solutions sharper, smarter, and more effective,”...

Volta Finance Limited (VTA / VTAS)May 2026 monthly report NOT FOR RELEASE, DISTRIBUTION, OR PUBLICATION, IN WHOLE OR PART, IN OR INTO THE UNITED STATES Guernsey, June 26th, 2026 BNPP AM has published the Volta Finance Limited (the “Company” or “Volta Finance” or “Volta”) monthly report for May 2026. The full report is attached to this release and will be available on Volta’s website shortly (www.voltafinance.com). Performance and Portfolio Activity Dear Investors, Volta Finance posted a net return of +0.0% for the month of May 2026. For comparison, US High Yield bonds returned +0.5%*** and Euro High Yield bonds achieved +1.1%**** over the same period, while the Morningstar Leveraged Loan indices returned +0.5%*** in the US and +0.7%**** in Europe. May was dominated by a renewed energy shock linked to the Middle East conflict, with disruptions...

AUSTIN, Texas, June 26, 2026 (GLOBE NEWSWIRE) — via IBN — Suntex Enterprises, Inc. (OTC: SNTX) today announced the successful completion and advancement of several significant corporate initiatives over the past two weeks, representing one of the Company’s strongest periods of operational execution since its strategic transformation. During this period, Suntex strengthened its corporate foundation, expanded its operating platform, advanced key growth initiatives, and continued delivering on commitments previously communicated to shareholders. Collectively, these accomplishments represent meaningful progress as the Company continues executing its long-term strategy of building a diversified platform of operating businesses across construction, infrastructure, development, manufacturing, land ownership, and consumer products. Key...

The Official Hard Seltzer of U.S. Soccer is offering what’s believed to be the largest single fan prize ever tied to American soccer, paying one believer $5 million if the U.S. Men’s National Team wins it allTRULY HARD SELTZER BETS $5 MILLION THAT U.S. SOCCER WILL WIN IT ALL, AND GIVES ONE FAN THE CHANCE TO CASH INThe Official Hard Seltzer of U.S. Soccer is offering what’s believed to be the largest single fan prize ever tied to American soccer, paying one believer $5 million if the U.S. Men’s National Team wins it allBOSTON, June 26, 2026 (GLOBE NEWSWIRE) — As the U.S. Men’s National Team continues its quest to win this summer’s international tournament, belief in the squad has never been stronger. Today, Truly Hard Seltzer, the Official Hard Seltzer of U.S. Soccer, is leading that belief by putting $5 million on the...

–Advisory Committee meeting scheduled for July 29, 2026––Company’s Biologics License Application on track with PDUFA target action date of August 22, 2026– SAN DIEGO, June 26, 2026 (GLOBE NEWSWIRE) — Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced that the Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) of the U.S. Food and Drug Administration (FDA) is planning to convene an advisory committee meeting to discuss the Company’s Biologics License Application (BLA) seeking approval of Deramiocel, an investigational cell therapy for the treatment of Duchenne muscular dystrophy (DMD). The BLA is supported by the Company’s Phase 2 HOPE-2 trial and long-term outcomes from the HOPE-2-OLE trial,...

VANCOUVER, British Columbia, June 26, 2026 (GLOBE NEWSWIRE) — Purecore Metals Inc. (CSE: PURE) (FSE: J8Y) (“Purecore” or the “Company”) is pleased to announce the commencement of a comprehensive data compilation program, representing the second phase of the Company’s 2026 exploration program at the Bankier Property (“Bankier”, “Project” or the “Property”). The Company holds a 100% interest in Bankier, an early-stage exploration project characterized by prospective alteration signatures and multi-element Mobile Metal Ion (MMI) anomalies in copper, molybdenum, gold, zinc, silver, lead, and uranium. The data compilation program includes:Digitizing historical rock, soil, MMI, and geophysical datasets to create interpretive maps and exploration vectoring toolsEstablishing an efficient data management system and project-wide...

26 June 2026, 15:15 CET ArcelorMittal (’the Company’) has today filed its 2025 Payments to Governments in respect of extractive activities report, which provides a consolidated overview of payments made by the Company and its subsidiaries in 2025 to governments regarding its mining operations. The report, which complies with reporting requirements under Luxembourg law, is available for download from https://corporate.arcelormittal.com/reports-and-policies. ENDS About ArcelorMittal ArcelorMittal is one of the world’s leading integrated steel and mining companies with a presence in 60 countries and primary steelmaking operations in 14 countries. It is the largest steel producer in Europe, among the largest in the Americas, and has a growing presence in Asia through its joint venture AM/NS India. ArcelorMittal sells its products to a diverse...

Company completed 28 consecutive trading days above $1.00 per share on June 25, 2026 Reverse stock split effectuated to ensure ongoing compliance with the Bid Price Rule and additional requirements from Nasdaq Hearings Panel MIRAMAR, Fla., June 26, 2026 (GLOBE NEWSWIRE) — HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation, focusing on autoimmune disorders and other inflammatory diseases, cancer and senescence-associated dysplasia, today announced that its Board of Directors has approved a 1-for-6 reverse stock split of the Company’s common stock, par value $0.0001 (“Common Stock”), which will be effective at 12:01 a.m. Eastern Time on June 30,...